• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Immix Biopharma Inc.

    5/2/25 7:51:44 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMMX alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
    (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☒ Definitive Additional Materials
       
    ☐ Soliciting Material under § 240.14a-12

     

    IMMIX BIOPHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required
       
    ☐ Fee paid previously with preliminary materials.
       
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     

     

     

     

     

     

     

    NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS

     

    The Annual Meeting of Stockholders of Immix Biopharma, Inc. will be held on

    June 20, 2025, at 12:00 p.m. EDT at the Company’s office located at

    11400 West Olympic Blvd., Suite 200, Los Angeles, California 90064

     

    PROXY STATEMENT AND 2024 ANNUAL REPORT ON FORM 10-K

    ARE AVAILABLE AT:

     

    https://annualgeneralmeetings.com/immx2025

     

     

    Dear Stockholder:

     

    The Annual Meeting of Stockholders of Immix Biopharma, Inc. has been called to consider and act upon the following matters:

     

      1. Election of eight directors;
         
      2. Ratification of Crowe LLP as Immix Biopharma’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    Our Board of Directors recommends a vote “FOR” all director nominees listed in proposal 1 and “FOR” proposal 2.

     

    You are receiving this communication because you hold shares in the company named above. Complete proxy materials, including the proxy card, which are available to you on-line at https://annualgeneralmeetings.com/immx2025 or upon your request by e-mail or first-class mail. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    This is not a ballot. You cannot use this notice to vote your shares. You may vote on-line, by mail or in person. If you wish to vote on-line, you will need your “Control Number” (which can be found in the bottom right hand corner of this notice) and the web address, all of which will be included with or on the proxy card located on the Internet website stated above or mailed to you at your request. No other personal information will be required in order to vote in this manner. If you wish to vote by mail, simply print out the proxy card located on the Internet website stated above, mark the proxy card accordingly, sign and return it to us at the address indicated on the proxy card. If you wish to vote in person at the Annual Meeting of Stockhold ers, simply check the box on the proxy card that you plan to attend. Your proxy card will not be used if you vote in person. Please check the meeting materials for any special requirements for meeting attendance. For directions to the meeting, please call (310) 651-8041.

     

     

     

     

    Important Notice Regarding the Availability of Proxy Materials

    for the Stockholder Meeting To Be Held on June 20, 2025:

     

      (1) This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

      (2) The Proxy Statement and 2024 Annual Report on Form 10-K are available at

    https://annualgeneralmeetings.com/immx2025.

     

      (3) If you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before June 8, 2025 to facilitate timely delivery.

     

    To request a paper copy of these items:

     

      ● Call our toll-free number 1-800-785-7782; or

     

      ● Visit our website at https://annualgeneralmeetings.com/immx2025; or

     

      ● Send us an e-mail at [email protected].

     

    Please clearly identify the items you are requesting; please also include the name “Immix Biopharma, Inc.”, your name along with the Control Number, located in the lower right hand corner of this notice, and the name and address to which the materials should be mailed.

     

      By Order of the Board of Directors
       
      /s/ Ilya Rachman
      Ilya Rachman
      Chairman and Chief Executive Officer

     

     

     

     

    Get the next $IMMX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMMX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMMX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

      Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi

      9/19/24 9:31:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

      LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9, 2024Presentation: Immix Biopharma to presentLocation:VirtualInvestor Meetings:The IMMX Team will be available for institutional investor meetings during the conference. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company

      6/17/24 9:35:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hsu Jason bought $104,358 worth of shares (47,700 units at $2.19), increasing direct ownership by 6% to 893,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      12/26/24 4:20:11 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/26/24 4:45:32 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/19/24 8:45:04 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Immix Biopharma Inc.

      SC 13G - Immix Biopharma, Inc. (0001873835) (Subject)

      2/7/24 9:18:36 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Immix Biopharma Inc.

      SC 13D - Immix Biopharma, Inc. (0001873835) (Subject)

      8/30/23 4:15:02 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Immix Biopharma Inc. (Amendment)

      SC 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)

      3/2/22 2:57:11 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Immix Biopharma Inc.

      10-Q - Immix Biopharma, Inc. (0001873835) (Filer)

      5/8/25 4:30:31 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Immix Biopharma Inc.

      DEFA14A - Immix Biopharma, Inc. (0001873835) (Filer)

      5/2/25 7:51:44 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Immix Biopharma Inc.

      SCHEDULE 13G/A - Immix Biopharma, Inc. (0001873835) (Subject)

      1/29/25 6:17:04 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hsu Jason bought $104,358 worth of shares (47,700 units at $2.19), increasing direct ownership by 6% to 893,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      12/26/24 4:20:11 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hsu Jason bought $51,623 worth of shares (23,100 units at $2.23), increasing direct ownership by 3% to 845,300 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/26/24 4:45:32 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ng Carey bought $18,600 worth of shares (10,000 units at $1.86), increasing direct ownership by 100% to 20,000 units (SEC Form 4)

      4 - Immix Biopharma, Inc. (0001873835) (Issuer)

      8/19/24 8:45:04 PM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

      Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

      6/10/24 1:09:24 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

      Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in the first FDA-approved therapy for AL amyloidosis Dr. Comenzo was the lead author on the landmark 2012 publication of consensus guidelines, including response criteria, for conduct and reporting of clinical trials in AL Amyloidosis LOS ANGELES, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Dr. Raymond Comenzo, internationally recognized AL Amyloidosis expert and Director of the Myeloma and Amyloid Program at Tufts Medi

      9/19/24 9:31:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

      LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

      6/10/24 8:30:00 AM ET
      $IMMX
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

      LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (("Immix Biopharma", "Company", "We" or "Us", NASDAQ:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Sanchorawala is internationally recognized for her pioneering work in development of novel agents to treat AL Amyloidosis, including the establishment of daratumumab as the standard of care. "Therapeutic landscape of AL amyloidosis is evolving. There is a marked progress in survival of patients with AL amyloidosis. However, better and more effective therapies are needed for those relapsing after Daratumumab based treatments. I am

      1/4/24 9:34:00 AM ET
      $IMMX
      Biotechnology: Pharmaceutical Preparations
      Health Care